Developer docs
API playgroundTry for free, no card

Search company profiles

ImmuONE

Full company profile

uuid0002oa4

Namestring
ImmuONE
Legal namestring
ImmuONE Ltd.
Websiteurl
immuone.com
Company typeenum
Private
Founded yearint
2019
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersStevenage, United Kingdom
HQ citystring
Stevenage
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in vitro lung models, inhalation toxicology services, contract research services, 3D cell culture, animal-free testing
Industry1 code
PRIMARYHLAGAFAH
Immunotoxicology & Immunogenicity Assessment
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Inhalation Toxicology Contract Research Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Research Services
TypeProfessional Services
Description

ImmuONE provides a wide range of in vitro toxicology testing services including inhalation toxicology, alveolar macrophage assessments, inflammation and immune response testing, drug discovery screening, and drug development support. Services are tailored to client needs with bespoke experimental design.

immuone.com
2Products (ImmuPHAGE™, ImmuLUNG™, LipidONE™)
TypeOne Time License
Description

Sale of proprietary cell culture models. ImmuPHAGE is available for purchase as a product. ImmuLUNG is currently available as part of ImmuONE's service packages with standalone product planned.

immuone.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Custom Service Packages
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is quote-based; ImmuONE offers tailored experimental design and services to address specific client inhalation safety assessment needs.

immuone.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 7 records shown
1ImmuLUNG™
Description

3D human lung model combining human alveolar epithelial cells and alveolar macrophage-like cells for inhalation safety assessment

immuone.com
+6 more records
Core offering1 text field

ImmuONE develops and sells proprietary 3D immune-competent human lung cell culture models (ImmuPHAGE™, ImmuLUNG™) and provides contract research services for inhalation safety assessment. The company's offerings include in vitro toxicology testing, alveolar macrophage assessments, inflammation and immune response testing, drug discovery screening, drug development support, and bespoke assay development using high-content imaging techniques, serving pharmaceutical, chemical, consumer products, and agrichemical companies as human-relevant alternatives to animal testing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Research shows approximately 90% of drugs shown safe in animals do not work as planned in humans, indicating the critical need for human-relevant testing models
+1 more record
Product overview1 text field

ImmuONE is a biotech company offering a portfolio of in vitro lung models and testing services focused on inhalation safety assessment. The core products include ImmuPHAGE™ (human alveolar macrophage-like model) and ImmuLUNG™ (3D co-culture combining epithelial cells and macrophages), along with the LipidONE™ assay service. Supporting services span assay development, inflammation and immune response testing, inhalation toxicology, drug discovery, drug development, and animal product-free testing solutions. The company uses advanced high-content imaging techniques including the morph_ONE™ assay to deliver multi-endpoint assessments from its laboratory facilities in Stevenage, UK.

Product and service10 records
1ImmuLUNG™
Category3D Lung Cell Culture Model
Description

Patented 3D co-culture model combining human alveolar epithelial cells and alveolar macrophage-like cells, providing immune-competent in vitro human airways models that maintain phenotype, morphology, and function for up to 14 days for inhalation safety assessment and drug testing. Currently available as part of ImmuONE's service packages, with standalone product planned.

2ImmuPHAGE™
CategoryAlveolar Macrophage Cell Model
Description

Patented human alveolar macrophage-like cell model for assessing immune responses to inhaled substances, characterized for cell structure, viability, phagocytic activity, and cytokine response. Available for direct purchase or for use within ImmuONE's contract research services.

3LipidONE™
CategoryAssay Service
Description

High-content imaging project using HCIA to characterise macrophage health, morphology, and lipid profiles, supporting safety assessment for macrophage responses where lipid accumulation is a concern, including phospholipidosis, autophagy, and atherosclerosis.

4morph_ONE™ Assay
CategoryAssay Service
Description

Multiparametric high-content imaging analysis tool that tracks subtle morphological shifts in macrophages by combining detailed cell morphology with cell health and biochemical readouts to classify macrophage responses and support safety assessment for foamy macrophages.

5Inflammation and Immune Response Services
CategoryContract Research Service
Description

Comprehensive in vitro alveolar macrophage assays evaluating cytokine activity, macrophage polarisation, phagocytic activity, and inflammatory responses for airways safety assessment. Designed for pharmaceutical and chemical companies requiring mechanistic immune response data on inhaled substances.

6Inhalation Toxicology Services
CategoryContract Research Service
Description

Preclinical in vitro testing services for inhaled product safety, including macrophage toxicology, epithelial toxicology, TEER measurements, LDH assays, and histological analysis. Delivered by ImmuONE's laboratory team in Stevenage.

7Animal Product-Free Services
CategoryContract Research Service
Description

Services adapted to be free of animal-derived products, particularly fetal bovine serum (FBS), replacing with chemically defined media for improved reproducibility and human relevance, aligned with regulatory trends toward animal-free testing.

8Drug Discovery Services
CategoryContract Research Service
Description

Drug screening services assessing toxicity, safety, and inflammatory responses in airways using ImmuPHAGE™ and ImmuLUNG™ models with cell painting assays to support early-stage candidate selection.

9Drug Development Services
CategoryContract Research Service
Description

Expert assistance in understanding inhaled biopharmaceutics from aerosolisation to deposition, including pharmacokinetic and pharmacodynamic assay support for inhaled therapeutics development.

10Assay Development Services
CategoryConsulting and Bespoke Assay Service
Description

On-demand cell assay development tailored to unique toxicity testing needs including high-content image analysis, image flow cytometry, flow cytometry, and immune-competent 3D models, delivered as bespoke consulting engagements.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-06-01
Description

Organ-on-a-chip company collaboration to test ImmuLUNG™ on AKITA® organ-on-a-chip platform under static and dynamic conditions, presented at MPS World Summit 2023.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

CRACK IT Challenge consortium working to establish and develop in vitro OECD test guidelines free from animal-derived products, improving human relevance and reproducibility.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-05-01
Description

Sponsor of NC3Rs CRACK IT Challenge Phase 2 supporting development of animal-product-free test guidelines.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-05-01
Description

Sponsor of NC3Rs CRACK IT Challenge Phase 2 supporting development of animal-product-free test guidelines.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-05-01
Description

Part of multi-disciplinary consortium for CRACK IT Challenge focused on serum replacement and in vitro innovations.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-05-01
Description

Academic partner in consortium for CRACK IT Challenge contributing expertise in pre-clinical assessment.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

US organ-on-chip company with the Emulate Liver-Chip, Lung-Chip, and other organ platforms used in preclinical drug development. Broad incumbent in the organ-on-chip category, with greater funding scale and broader portfolio than ImmuONE, competing for the same NAMs-driven CRO wallet.

2Kirkstall
TypeEmerging player
Description

UK-based organ-on-chip company with the Quasi Vivo multi-organ platform, including lung modules for inhalation toxicology. Emerging peer based in the same UK biotech cluster with comparable preclinical in vitro technology focus.

TypeDirect peer
Description

Swiss 3D in vitro microtissue technology company providing organotypic models for drug safety and efficacy testing. Direct peer in 3D human-relevant preclinical models with comparable CRO services and pharmaceutical customer focus.

TypeBroad incumbent
Description

UK-based preclinical CRO (acquired by Evotec) specializing in in vitro ADME-Tox and safety assessment services for pharmaceutical clients. Broad incumbent in the in vitro preclinical space, with overlapping toxicology service offerings and similar UK positioning.

TypeDirect peer
Description

Swiss-based developer of 3D in vitro human airway models (MucilAir, SmallAir) used for respiratory toxicology and drug efficacy testing. Direct competitor to ImmuONE in the immune-competent in vitro airway safety assessment space, serving similar pharmaceutical and chemical clients.

TypeEmerging player
Description

Dutch organ-on-chip company developing the OrganoPlate platform for disease modeling and toxicology, including inflammatory and respiratory applications. Emerging peer with partial overlap in in vitro NAMs for pharmaceutical R&D.

TypeBroad incumbent
Description

Global CRO offering inhalation toxicology, safety assessment, and clinical/preclinical drug development services. Broad incumbent with deep pharma client relationships, posing competitive risk to ImmuONE's contract research services revenue.

8CN Bio Innovations
TypeDirect peer
Description

UK organ-on-chip company developing microphysiological systems including lung and liver models for preclinical drug development. Direct peer in the human-relevant in vitro inhalation/toxicology space, with overlapping pharma customer base and similar regulatory NAMs positioning.

TypeBroad incumbent
Description

Global preclinical CRO providing inhalation toxicology, safety assessment, and drug development services to pharmaceutical and chemical clients. Broad incumbent whose scale and established client relationships could absorb or replicate ImmuONE's specialist offering.

TypeDirect peer
Description

US-based developer of 3D in vitro human airway epithelial tissue models (EpiAirway) for toxicology, drug delivery, and disease research. Direct peer in reconstructed human airway models for inhalation safety testing, serving overlapping pharmaceutical and consumer products customers.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ImmuONE

Inhalation Toxicology Contract Research Servicesimmuone.com

ImmuONE firmographics

Firmographics
Name
ImmuONE
Legal name
ImmuONE Ltd.
Website
https://immuone.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

ImmuONE industry classification

Industry
Product category
Inhalation Toxicology Contract Research Services
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAFAH
Immunotoxicology & Immunogenicity Assessment
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • In vitro lung models
  • Inhalation toxicology services
  • Contract research services
  • 3D cell culture
  • Animal-free testing

Where ImmuONE is headquartered

Location

Headquarters

HQ city
Stevenage
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

ImmuONE business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services: ImmuONE provides a wide range of in vitro toxicology testing services including inhalation toxicology, alveolar macrophage assessments, inflammation and immune response testing, drug discovery screening, and drug development support. Services are tailored to client needs with bespoke experimental design.
  2. Products (ImmuPHAGE™, ImmuLUNG™, LipidONE™): Sale of proprietary cell culture models. ImmuPHAGE is available for purchase as a product. ImmuLUNG is currently available as part of ImmuONE's service packages with standalone product planned.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom Service Packages

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

ImmuONE product offering

Product offering

Core offering

ImmuONE develops and sells proprietary 3D immune-competent human lung cell culture models (ImmuPHAGE™, ImmuLUNG™) and provides contract research services for inhalation safety assessment. The company's offerings include in vitro toxicology testing, alveolar macrophage assessments, inflammation and immune response testing, drug discovery screening, drug development support, and bespoke assay development using high-content imaging techniques, serving pharmaceutical, chemical, consumer products, and agrichemical companies as human-relevant alternatives to animal testing.

Product overview

ImmuONE is a biotech company offering a portfolio of in vitro lung models and testing services focused on inhalation safety assessment. The core products include ImmuPHAGE™ (human alveolar macrophage-like model) and ImmuLUNG™ (3D co-culture combining epithelial cells and macrophages), along with the LipidONE™ assay service. Supporting services span assay development, inflammation and immune response testing, inhalation toxicology, drug discovery, drug development, and animal product-free testing solutions. The company uses advanced high-content imaging techniques including the morph_ONE™ assay to deliver multi-endpoint assessments from its laboratory facilities in Stevenage, UK.

Differentiator

Problem solved

Functional benefit

Brands

  • ImmuLUNG™: 3D human lung model combining human alveolar epithelial cells and alveolar macrophage-like cells for inhalation safety assessment
  • ImmuPHAGE™
  • LipidONE™
  • morph_ONE™
  • ImmuONE_Discover™
  • ImmuONE_EXPLORE™
  • ImmuONE_Workshops™

Products and services

  • ImmuLUNG™ Patented 3D co-culture model combining human alveolar epithelial cells and alveolar macrophage-like cells, providing immune-competent in vitro human airways models that maintain phenotype, morphology, and function for up to 14 days for inhalation safety assessment and drug testing. Currently available as part of ImmuONE's service packages, with standalone product planned.
  • ImmuPHAGE™ Patented human alveolar macrophage-like cell model for assessing immune responses to inhaled substances, characterized for cell structure, viability, phagocytic activity, and cytokine response. Available for direct purchase or for use within ImmuONE's contract research services.
  • LipidONE™ High-content imaging project using HCIA to characterise macrophage health, morphology, and lipid profiles, supporting safety assessment for macrophage responses where lipid accumulation is a concern, including phospholipidosis, autophagy, and atherosclerosis.
  • morph_ONE™ Assay Multiparametric high-content imaging analysis tool that tracks subtle morphological shifts in macrophages by combining detailed cell morphology with cell health and biochemical readouts to classify macrophage responses and support safety assessment for foamy macrophages.
  • Inflammation and Immune Response Services Comprehensive in vitro alveolar macrophage assays evaluating cytokine activity, macrophage polarisation, phagocytic activity, and inflammatory responses for airways safety assessment. Designed for pharmaceutical and chemical companies requiring mechanistic immune response data on inhaled substances.
  • Inhalation Toxicology Services Preclinical in vitro testing services for inhaled product safety, including macrophage toxicology, epithelial toxicology, TEER measurements, LDH assays, and histological analysis. Delivered by ImmuONE's laboratory team in Stevenage.
  • Animal Product-Free Services Services adapted to be free of animal-derived products, particularly fetal bovine serum (FBS), replacing with chemically defined media for improved reproducibility and human relevance, aligned with regulatory trends toward animal-free testing.
  • Drug Discovery Services Drug screening services assessing toxicity, safety, and inflammatory responses in airways using ImmuPHAGE™ and ImmuLUNG™ models with cell painting assays to support early-stage candidate selection.
  • Drug Development Services Expert assistance in understanding inhaled biopharmaceutics from aerosolisation to deposition, including pharmacokinetic and pharmacodynamic assay support for inhaled therapeutics development.
  • Assay Development Services On-demand cell assay development tailored to unique toxicity testing needs including high-content image analysis, image flow cytometry, flow cytometry, and immune-competent 3D models, delivered as bespoke consulting engagements.

Quantifiable outcome

  • Research shows approximately 90% of drugs shown safe in animals do not work as planned in humans, indicating the critical need for human-relevant testing models
  • +1 more outcomes

Companies that use ImmuONE

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

ImmuONE technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

ImmuONE partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • FinnAdvancecoreTechnology or Integration · 1 June 2023Organ-on-a-chip company collaboration to test ImmuLUNG™ on AKITA® organ-on-a-chip platform under static and dynamic conditions, presented at MPS World Summit 2023.
  • NC3RscoreStrategic or Co-development Partner · 1 January 2022CRACK IT Challenge consortium working to establish and develop in vitro OECD test guidelines free from animal-derived products, improving human relevance and reproducibility.
  • UnilevercoreStrategic or Co-development Partner · 1 May 2021Sponsor of NC3Rs CRACK IT Challenge Phase 2 supporting development of animal-product-free test guidelines.
  • AstraZenecacoreStrategic or Co-development Partner · 1 May 2021Sponsor of NC3Rs CRACK IT Challenge Phase 2 supporting development of animal-product-free test guidelines.
  • PAN BiotechminorStrategic or Co-development Partner · 1 May 2021Part of multi-disciplinary consortium for CRACK IT Challenge focused on serum replacement and in vitro innovations.
  • University of OxfordminorStrategic or Co-development Partner · 1 May 2021Academic partner in consortium for CRACK IT Challenge contributing expertise in pre-clinical assessment.

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

ImmuONE competitors and assessment

Company assessment

Broad incumbents

  • Emulate Inc: US organ-on-chip company with the Emulate Liver-Chip, Lung-Chip, and other organ platforms used in preclinical drug development. Broad incumbent in the organ-on-chip category, with greater funding scale and broader portfolio than ImmuONE, competing for the same NAMs-driven CRO wallet.
  • Cyprotex (Evotec): UK-based preclinical CRO (acquired by Evotec) specializing in in vitro ADME-Tox and safety assessment services for pharmaceutical clients. Broad incumbent in the in vitro preclinical space, with overlapping toxicology service offerings and similar UK positioning.
  • Labcorp Drug Development (Covance): Global CRO offering inhalation toxicology, safety assessment, and clinical/preclinical drug development services. Broad incumbent with deep pharma client relationships, posing competitive risk to ImmuONE's contract research services revenue.
  • Charles River Laboratories: Global preclinical CRO providing inhalation toxicology, safety assessment, and drug development services to pharmaceutical and chemical clients. Broad incumbent whose scale and established client relationships could absorb or replicate ImmuONE's specialist offering.

Emerging players

  • Kirkstall: UK-based organ-on-chip company with the Quasi Vivo multi-organ platform, including lung modules for inhalation toxicology. Emerging peer based in the same UK biotech cluster with comparable preclinical in vitro technology focus.
  • MIMETAS: Dutch organ-on-chip company developing the OrganoPlate platform for disease modeling and toxicology, including inflammatory and respiratory applications. Emerging peer with partial overlap in in vitro NAMs for pharmaceutical R&D.

Direct peers

  • InSphero: Swiss 3D in vitro microtissue technology company providing organotypic models for drug safety and efficacy testing. Direct peer in 3D human-relevant preclinical models with comparable CRO services and pharmaceutical customer focus.
  • Epithelix: Swiss-based developer of 3D in vitro human airway models (MucilAir, SmallAir) used for respiratory toxicology and drug efficacy testing. Direct competitor to ImmuONE in the immune-competent in vitro airway safety assessment space, serving similar pharmaceutical and chemical clients.
  • CN Bio Innovations: UK organ-on-chip company developing microphysiological systems including lung and liver models for preclinical drug development. Direct peer in the human-relevant in vitro inhalation/toxicology space, with overlapping pharma customer base and similar regulatory NAMs positioning.
  • MatTek (EpiAirway): US-based developer of 3D in vitro human airway epithelial tissue models (EpiAirway) for toxicology, drug delivery, and disease research. Direct peer in reconstructed human airway models for inhalation safety testing, serving overlapping pharmaceutical and consumer products customers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

ImmuONE social profiles

Digital presence

ImmuONE financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ImmuONE leadership team

Management profile

Number of profiles

Profiles15 records

ImmuONE funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ImmuONE M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ImmuONE

What does ImmuONE do?

ImmuONE develops and sells proprietary 3D immune-competent human lung cell culture models (ImmuPHAGE™, ImmuLUNG™) and provides contract research services for inhalation safety assessment. The company's offerings include in vitro toxicology testing, alveolar macrophage assessments, inflammation and immune response testing, drug discovery screening, drug development support, and bespoke assay development using high-content imaging techniques, serving pharmaceutical, chemical, consumer products, and agrichemical companies as human-relevant alternatives to animal testing.

Is ImmuONE a public or private company?

ImmuONE is a private company. It is classified as venture growth investor backed and is currently operating.

When was ImmuONE founded?

ImmuONE was founded in 2019. It employs 11 to 50 people.

Where is ImmuONE based?

ImmuONE is headquartered in Stevenage, United Kingdom, in the Europe region.

How does ImmuONE make money?

Two revenue lines are on record. Contract Research Services are the primary driver. The others are products (ImmuPHAGE™, ImmuLUNG™, LipidONE™).

Who are ImmuONE's main competitors?

Broad incumbents on record are Emulate Inc, Cyprotex (Evotec), Labcorp Drug Development (Covance) and Charles River Laboratories. Emerging players are Kirkstall and MIMETAS. Direct peers are InSphero, Epithelix, CN Bio Innovations and MatTek (EpiAirway).

Does ImmuONE have an API?

No public API is recorded for ImmuONE.

What industry is ImmuONE in?

ImmuONE's product category is Inhalation Toxicology Contract Research Services. Its primary akta.pro industry code is HLAGAFAH, Immunotoxicology & Immunogenicity Assessment. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ImmuoneImmuONE raises £600K in investment for ‘3D lung’ to replace animal testingImmuONE, a UK biotech with a 3D lung model, raised £600,000 from Midlands Engine Investment Fund, Mercia Ventures, and Pioneer Group. The funding will support development, new sectors like agrichemicals and automotive, and hiring two scientists. The company expects to double revenue again in 2025.StartupmagImmuONE Secures £600K to Enhance Ethical Testing MethodsImmuONE, a Stevenage-based biotech startup, raised £600,000 in pre-seed funding from investors including Midlands Engine Investment Fund, Mercia Ventures, and Pioneer Group. The funds will support its 3D human lung model for respiratory safety assessments and expand into agrichemicals and automotive sectors.BioPharmaTrendUK Company Secures £600,000 for 3D Lung Model to Replace Animal TestingImmuONE, a UK biotech firm, secured £600,000 in follow-on funding from Midlands Engine, Mercia Ventures, and the Pioneer Group. The funds will support expansion into agrichemicals and automotive, and hiring two scientists. The company expects similar revenue growth in 2025.PharmiWeb.comImmuONE secures funding for ‘3D lung’ to replace animal testingImmuONE, a UK biotech using a 3D lung model to replace animal testing, raised £600,000 from Midlands Engine Investment Fund, Mercia Ventures, and Pioneer Group. The funding will support expanding services into agrichemicals and automotive, and hiring two scientists. The company expects to double revenue again in 2025.ItvCould this artificial '3D lung' developed in Stevenage spell the end of animal testing?ImmuONE scientists in Stevenage developed a 3D cell model of human lung tissue to test inhaled products. The model could replace animal testing for inhalation safety, potentially ending the need for animal studies in many cases. The company secured £2m funding to expand its laboratories.Business WeeklyImmuONE raises £2m for 3D human lung model to replace animal testingImmuONE has secured £2 million in funding from the MEIF Proof of Concept & Early Stage Fund to expand its operations and develop a 3D human lung model that replaces animal testing. The investment will support the company's move to new headquarters in Milton Keynes and laboratories in Stevenage, enabling it to grow its team by six and increase capacity for its global customer base.ThepioneergroupPioneer Group Announces Participation In £2m Investment In 3D Drug Development Innovator ImmuONEPioneer Group has participated in a £2 million financing round for ImmuONE, a biotech firm developing 3D human lung models to assess drug safety without animal testing. The investment, which also includes backing from the Midlands Engine Investment Fund via Mercia Ventures, will support ImmuONE's expansion into new headquarters and laboratories. This funding aims to scale the company's operations as it seeks to replace invasive or inaccurate traditional testing methods with more reliable 3D models.ImmuoneScientists raise £2m for 3D human lung model to replace animal testingImmuONE, a biotech company founded by Dr Abigail Martin and Professor Victoria Hutter, has secured £2m in investment from the MEIF Proof of Concept & Early Stage Fund to scale its 3D human lung model technology. The funding will support the company's move to new headquarters in Milton Keynes and laboratories in Stevenage, enabling expansion of operations and creation of six new jobs. This development aims to replace animal testing with more accurate human tissue models for drug and chemical safety assessments.BusinessCloudCompany behind 3D human lung raises £2mImmuONE, a company developing a 3D human lung model for drug safety testing, raised £2m from MEIF. The funding will support expansion into new headquarters and laboratories, with plans for six new jobs. The company has generated over £1m in revenue since its launch.BusinessCloudCompany behind 3D human lung raises £2mImmuONE, a company developing a 3D human lung model for drug safety testing, raised £2m from MEIF. The funding will support expansion into new headquarters and laboratories, with plans for six new jobs. The company has generated over £1m in revenue since its launch.